What is LIBTAYO?

LIBTAYO (Lib-TIE-oh) is a type of immunotherapy called a programmed death receptor-1 (PD-1) inhibitor. LIBTAYO is not chemotherapy or radiation therapy.

LIBTAYO may be right for people with advanced NSCLC who have tumors that test positive for high PD-L1 (PD-L1 levels greater than or equal to 50%) and the tumor does not have an abnormal EGFR, ALK, or ROS1 gene, and whose NSCLC:

Portrayal of Advanced NSCLC that has not spread outside the chest

Has not spread outside the chest (locally advanced lung cancer)


AND
Portrayal of Advanced NSCLC that cannot be cured by surgery or chemotherapy with radiation

Cannot have surgery or chemotherapy with radiation


OR
Portrayal of Advanced NSCLC that has spread to other areas of the body

Has spread to other areas of the body (metastatic lung cancer)

ALK=anaplastic lymphoma kinase; EGFR=epidermal growth factor receptor; PD-L1=programmed death ligand 1; ROS1=ROS proto-oncogene 1, receptor tyrosine kinase.

LIBTAYO works with your immune system to help treat advanced NSCLC.

Learn how LIBTAYO works